Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
First Wave BioPharma Completes Business Combination with ImmunogenX, Adding Latiglutenase
Details : Through acquisition, First Wave advances its lead product IMGX003 (latiglutenase) for treating celiac disease, currently under Phase II clinical trials.
Brand Name : IMGX003
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Details : Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac...
Brand Name : IMGX003
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Mayo Clinic
Deal Size : Not Applicable
Deal Type : Not Applicable
ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology
Details : The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patie...
Brand Name : IMGX003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 12, 2022
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Mayo Clinic
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Latiglutenase
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
ImmunogenX and Mayo Clinic Successfully Complete the CeliacShield Trial
Details : CeliacShield Trial is a double-blind, placebo controlled, gluten challenge trial of the efficacy, safety and tolerability of 6-weeks treatment of Latiglutenase (IMGX003) administration in patients with well-controlled celiac disease.
Brand Name : IMGX003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2021
Lead Product(s) : Latiglutenase
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease
Details : The trial will test the safety and efficacy of the company’s lead therapeutic candidate, Latiglutenase (IMGX003).
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 13, 2020
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?